Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Initially the hypothalamic factor responsible for the release of corticotropin (CRF), was thought to be a simple peptide. More recent work has led to the conclusion that CRF is a multifactorial complex. In 1979 we proposed that vasopressin, much disputed as a CRF candidate, was a major constituent of the complex, interacting with a potentiating the CRF activity of the other component(s). The recent characterization of a 41 residue ovine hypothalamic peptide capable of releasing adrenocorticotropic hormone (ACTH) in a dose-related manner has allowed us to compare its CRF bioactivity with that of vasopressin and simple extracts of the hypothalamus, and to investigate any interaction it may have with vasopressin and other hypothalamic factors in the release of ACTH. We report here that the new CRF is more potent than vasopressin in releasing ACTH. When given simultaneously with vasopressin a fourfold potentiation of CRF activity with steep dose-response characteristics were observed. It also potentiated vasopressin-free hypothalamic extracts, suggesting that a new CRF does not account for all the nonvasopressin portion of the CRF complex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Their synergistic stimulation of ACTH production and secretion by corticotrope cells could yield a several-fold higher output than due to the action of either one individually (26, 34–41, 43–47).”
From Influence of arginine vasopressin on the ultradian dynamics of Hypothalamic-Pituitary-Adrenal axis (2022) · cites this paper as [36]
In the citing paper
“Namely, it has been indicated that both CRH and AVP act on their own receptors (28–32) on corticotrope cells in anterior pituitary to stimulate adrenocorticotropic hormone (ACTH) production and release with different (26, 33–41) or even similar potencies (42).”
From Influence of arginine vasopressin on the ultradian dynamics of Hypothalamic-Pituitary-Adrenal axis (2022) · cites this paper as [36]
In the citing paper
“Namely, both in human (39, 43–47, 55) and in rat (26, 36–38, 40, 41), CRH reaction pathway is considered to be dominant in pituitary-adrenal regulation.”
From Influence of arginine vasopressin on the ultradian dynamics of Hypothalamic-Pituitary-Adrenal axis (2022) · cites this paper as [36]
In the citing paper
“Corticotropin-releasing hormone and AVP interact at the level of the anterior pituitary (16)”
From Progesterone does not alter osmotic regulation of AVP (2001) · cites this paper as [16]
In the citing paper
“Furthermore, VP stimulates adrenocorticotropin hormone release through the activation of pituitary V1bR [10,11].”
From Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats (2015) · cites this paper as [10]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Schally, A. V., Arimura, A., & Kastin, A. J. (1973) · Science · doi:10.1126/science.179.4071.341 · Cited by 572
Frontiers in Neuroendocrinology
Ball, J. B. (1975) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197501000-00019 · Cited by 426
FRONTIERS IN NEUROENDOCRINOLOGY
Kennedy, G. C. (1970) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.33.5.719 · Cited by 357
Corticotrophin releasing factor may be modulated vasopressin
GILLIES, G., & LOWRY, P. (1979) · Nature · doi:10.1038/278463a0 · Cited by 174
Self-citationHypothalamic Releasing Factors
Burgus, R. C., & Guillemin, R. (1970) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.39.070170.002435 · Cited by 129
Gillies, G. E., & Lowry, P. J. (1978) · Endocrinology · doi:10.1210/endo-103-2-521 · Cited by 106
Self-citationZimmerman, E. A., Stillman, M. A., Recht, L. D., Antunes, J. L. F., Carmel, P. W., & Goldsmith, P. C. (1977) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1977.tb41872.x · Cited by 97
Gillies, G. E., Greidanus, T. B. V. W., & Lowry, P. J. (1978) · Endocrinology · doi:10.1210/endo-103-2-528 · Cited by 60
Self-citation
Research works printed but not linked: 5
- Royce, P. C. & Sayers, G. Proc. Soc. exp. Biol. Med. 142, 842–845 (1960).
- Gillies, G. & Lowry, P. J. in Interactions within the Brain-Pituitary-Adrenocortical System (eds Jones, Gilham, Dallman & Chattopadhyay) 51–61 (Academic, New York, 1979).
- Sokol, H. W. & Zimmerman, E. A. Ann. N.Y. Acad. Sci. (in the press).
- Zimmerman, E. A. in Frontiers of Neuroendocrinology Vol. 4 (eds Martini, L. & Ganong, W. F.) 25–62 (Raven, New York, 1976).
- Baertischi, A. in Neuroendocrinology of Vasopressin, Corticoliberin and Opiomelanocortin (eds Baertischi, A. & Driefuss, J.-J.) (Academic, London, in the press).
Cited by
Items 201–300 of 971
Walker, C., Toufexis, D. J., & Burlet, A. J. (2001) · Progress in brain research · doi:10.1016/s0079-6123(01)33008-x · Cited by 107
Kiss, A., & Aguilera, G. (1993) · Brain Research · doi:10.1016/0006-8993(93)90665-a · Cited by 98
Antoni, F. A., Holmes, M. C., Makara, G. B., Kárteszi, M., & László, F. A. (1984) · Peptides · doi:10.1016/0196-9781(84)90080-9 · Cited by 98
Herbert, J. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90033-o · Cited by 98
Suzuki, S., & Handa, R. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20457 · Cited by 97
“AVP is also known to be involved in the regulation of the HPA axis (Gillies et al., 1982; Whitnall et al., 1985; Rittmaster et al., 1987).”
BackgroundAguilera, G., Pham, Q., & Rabadan‐Diehl, C. (1994) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1994.tb00586.x · Cited by 96
“However, the relative importance of VP in the multifactorial regulation of ACTH secretion began to be understood only after the characterization of the 41 -aminoacid corticotropin releasing hormone (CRH) (5-8).”
BackgroundBradbury, M. J., Akana, S. F., Cascio, C. S., Levin, N., Jacobson, L., & Dallman, M. F. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90176-6 · Cited by 96
Tsagarakis, S. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1646 · Cited by 94
Neuropeptides in the Amphibian Brain
Andersen, A. C., Tonon, M., Pelletier, G., Conlon, J. M., Fasolo, A., & Vaudry, H. (1992) · International review of cytology · doi:10.1016/s0074-7696(08)61588-0 · Cited by 98
Burrows, H. L., Nakajima, M., Lesh, J. S., Goosens, K. A., Samuelson, L. C., Inui, A., Camper, S. A., & Seasholtz, A. F. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1963 · Cited by 95
“Alternatively, an increase in AVP, an ACTH secretagogue that potentiates the activity of CRH (23), could normalize ACTH production.”
BackgroundMarler, C. A., Chu, J., & Wilczynski, W. (1995) · Hormones and Behavior · doi:10.1006/hbeh.1995.1286 · Cited by 96
“AVT injections increase corticosterone in the frogs Xenopus laevis (Kloas and Hanke, 1990) and Rana temporia (Hanke and Maser, 1985), a response similar to that found in mammals when given artificially increased levels of AVP (e.g., Gillies, Linton, and Lowry, 1982).”
BackgroundBuma, P., & Nieuwenhuys, R. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90141-8 · Cited by 100
Claudine, S.-L. G., Sylvain, D., Gabrielle, B., Maurice, M., Jacques, S., Rolf, G., Guy, G., & Gilles, G. (2003) · Stress · doi:10.1080/1025389032000114524 · Cited by 92
“VP exerts a dual effect as a direct ACTH secretagogue and also potentiates the stimulatory effect of corticotropin releasing factor (CRF) (Gillies et al., 1982).”
BackgroundInfluentialThe role of CRF in the release of ACTH by opiate agonists and antagonists in rats
Nikolarakis, K. E., Pfeiffer, A. F. H., Stalla, G. K., & Herz, A. (1987) · Brain Research · doi:10.1016/0006-8993(87)91311-4 · Cited by 91
Liu, J. P., Robinson, P. J., Funder, J. W., & Engler, D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77278-5 · Cited by 91
Regulation of pituitary corticotropin releasing hormone receptors
Aguilera, G., Rabadan‐Diehl, C., & Nikodémová, M. (2001) · Peptides · doi:10.1016/s0196-9781(01)00390-4 · Cited by 106
The endocrine response to critical illness
Rolih, C. A., & Ober, K. P. (1995) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30093-1 · Cited by 96
Liposits, Z., Uht, R. M., Harrison, R. W., Gibbs, F. P., Paull, W. K., & Bohn, M. C. (1987) · Histochemistry and Cell Biology · doi:10.1007/bf00496811 · Cited by 91
“1981), whose action is potentiated by arginine vasopressin (AVP) (Gillies et al. 1982), is a potent stimulator of adenohypophyseal fl-endorphin and adrenocorticotropin (ACTH) secretion (Vale etal.”
BackgroundAdrenergic control of the secretion of anterior pituitary hormones
Al‐Damluji, S. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80180-6 · Cited by 90
Glucocorticoids, Transmitters and Stress
Delbende, C., Delarue, C., Lefebvre, H., Bunel, D. T., Szafarczyk, A., Mocaër, E., Kamoun, A., Jégou, S., & Vaudry, H. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296657 · Cited by 90
Schmidt, E. D., Binnekade, R., Janszen, A. W. J. W., & Tilders, F. J. H. (1996) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1996.tb00707.x · Cited by 89
O’Carroll, A., Don, A. L. J., & Lolait, S. J. (2003) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2003.01102.x · Cited by 89
Arginine Vasopressin Is Associated with Hypercortisolemia and Suicide Attempts in Depression
Inder, W. J., Donald, R. A., Prickett, T. C. R., FRAMPTON, C. M. A., Sullivan, P. F., Mulder, R., & Joyce, P. R. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00301-6 · Cited by 96
Swain, M. G., Patchev, V, Vergalla, J., Chrousos, G., & Jones, E. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116408 · Cited by 91
Neuroimmune Regulation in Immunocompetence, Acute Illness, and Healing
Berczi, I., Quintanar‐Stephano, A., & Kovacs, K. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2008.03975.x · Cited by 87
Optical Multibead Arrays for Simple and Complex Odor Discrimination
Albert, K. J., Walt, D. R., Gill, D. S., & Pearce, T. (2001) · Analytical Chemistry · doi:10.1021/ac001137a · Cited by 89
Hannibal, J., Mikkelsen, J. D., Fahrenkrug, J., & Larsen, P. J. (1995) · Endocrinology · doi:10.1210/endo.136.9.7649120 · Cited by 89
Neuroendocrine Mechanisms and the Precipitation of Depression by Life Events
Checkley, S. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296633 · Cited by 87
Modulation of transmitter and hormone release by multiple neuronal opioid receptors
Illés, P. (2005) · Springer eBooks · doi:10.1007/bfb0027497 · Cited by 88
SUDA, T., TOZAWA, F., USHIYAMA, T., TOMORI, N., SUMITOMO, T., NAKAGAMI, Y., YAMADA, M., DEMURA, H., & SHIZUME, K. (1989) · Endocrinology · doi:10.1210/endo-124-3-1444 · Cited by 88
Samson, W. K. (1985) · Endocrinology · doi:10.1210/endo-117-3-1279 · Cited by 88
Petrides, J. S. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.2.377 · Cited by 86
Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla
Grazzini, E. (1996) · Endocrinology · doi:10.1210/en.137.9.3906 · Cited by 87
Bilezikjian, L. M., Blount, A. L., & Vale, W. W. (1987) · Molecular Endocrinology · doi:10.1210/mend-1-7-451 · Cited by 89
PIETERS, G. F. F. M., Hermus, A. R. M. M., SMALS, A. G. H., Bartelink, A. K. M., Benraad, T. J., & KLOPPENBORG, P. W. C. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-3-513 · Cited by 87
Regulation of Pituitary Vasopressin V1b Receptor mRNA during Stress in the Rat
Rabadan‐Diehl, C., Lolait, S. J., & Aguilera, G. (1995) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1995.tb00734.x · Cited by 86
“Although magnoand appears to have an important physiological role in modulating cellular VP can access the pituitary portal circulation and stimuthe effects of CRH in the corticotroph (1-4).”
BackgroundTaveau, C., Chollet, C., Waeckel, L., Desposito, D., Bichet, D. G., Arthus, M.-F., Magnan, C., Philippe, E., Paradis, V., Foufelle, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3496-9 · Cited by 86
“Previous studies have evaluated the role of VP and VP receptors on glucose tolerance using VP-deficient rat or mice with inactivation of V1aR and/or V1bR.”
InfluentialKiyokawa, Y., Hiroshima, S., Takeuchi, Y., & Mori, Y. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.12.005 · Cited by 95
“Moreover, unlike the parvocellular neurons that secrete the corticotrophin-releasing hormone, those secreting oxytocin and vasopressin do not directly contribute to HPA axis activation in response to acute stressors (Gillies et al., 1982).”
De Keyzer, Y., René, P., Beldjord, C., Lenne, F., & Bertagna, X. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00560.x · Cited by 87
“This might be important, since CRH is the major positive regulator of POMC gene expression and since these two receptors, although coupled to different signalling pathways, act synergistically to stimulate POMC expression (Gillies et al., 1982).”
BackgroundReisine, T., Rougon, G., Barbet, J., & Affolter, H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.8261 · Cited by 86
Role of interleukin-1 in stress responses: A putative neurotransmitter
Shintani, F., Nakaki, T., Kanba, S., Kato, R., & Asai, M. (1995) · Molecular Neurobiology · doi:10.1007/bf02740837 · Cited by 85
(1991) · PubMed · Cited by 85
Croiset, G., Nijsen, M., & Kamphuis, P. J. G. H. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00556-2 · Cited by 103
van Leeuwen, F. W., & Wolters, P. S. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90223-9 · Cited by 84
Chrousos, G. P. (1998) · Endocrinology · doi:10.1210/endo.139.2.5857 · Cited by 83
Cizza, G. (1994) · Endocrinology · doi:10.1210/en.134.4.1611 · Cited by 86
Giguère, V., & Labrie, F. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91171-3 · Cited by 83
Hastings, M. H. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90072-t · Cited by 97
Phenotypic Plasticity of CRF Neurons during Stressa
Tilders, F. J. H., Schmidt, E. D., & de Goeij, D. C. E. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb49921.x · Cited by 83
Elias, L. L. K., Antunes‐Rodrigues, J., Elias, P. C. L., & Moreira, A. C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.4.3884 · Cited by 82
Ma, X.-M. (1999) · Endocrinology · doi:10.1210/en.140.12.5642 · Cited by 82
Identification and Characterization of Arginine Vasopressin Receptors in the Rat Testis*
MEIDAN, R., & HSUEH, A. J. W. (1985) · Endocrinology · doi:10.1210/endo-116-1-416 · Cited by 81
Liu, J. P., Clarke, I. J., Funder, J. W., & Engler, D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117121 · Cited by 81
“The effect of CRFon ACTHrelease is potentiated by arginine vasopressin (AVP), oxytocin, angiotensin II, and the catecholamines norepinephrine and epinephrine (5, 6).”
BackgroundMurphy, D., Levy, A., Lightman, S., & Carter, D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.9002 · Cited by 81
WATANABE, T., & ORTH, D. N. (1987) · Endocrinology · doi:10.1210/endo-121-3-1133 · Cited by 80
Interleukin‐1β and lnterleukin‐6 Stimulate Neurohypophysial Hormone Release in vitro
Yasin, S. A., Costa, A., Forsling, M. L., & Grossman, A. (1994) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1994.tb00570.x · Cited by 81
“AVP has been shown to stimulate ACTH release and also potentiates the stimulatory effect of CRH on ACTH release (16, 21-23).”
BackgroundEngler, D., Redei, E., & Kola, I. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0376 · Cited by 79
Opioid modulation of magnocellular neurosecretory cell activity
Brown, C. H., Russell, J. A., & Leng, G. (2000) · Neuroscience Research · doi:10.1016/s0168-0102(99)00121-2 · Cited by 86
“, 1983) that act synergistically to control adrenocorticotrophic hormone secretion from the anterior pituitary (Gillies et al., 1982).”
BackgroundCastro, M. G., Estivariz, F. E., & Iturriza, F. C. (1986) · Comparative Biochemistry and Physiology Part A Physiology · doi:10.1016/0300-9629(86)90090-3 · Cited by 79
Glucocorticoids Increase Vasopressin V1b Receptor Coupling to Phospholipase C
Rabadan-Diehl, C., & Aguilera, G. (1998) · Endocrinology · doi:10.1210/endo.139.7.6121 · Cited by 78
Fischer, D., Patchev, V. K., Hellbach, S., Hassan, A. H., & Almeida, O. F. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118153 · Cited by 80
Gomez, M. T. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.1.173 · Cited by 80
Kalogeras, K. T., Nieman, L. K., Friedman, T. C., Doppman, J. L., Cutler, G. B., Chrousos, G. P., Wilder, R. L., Gold, P. W., & Yanovski, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118640 · Cited by 81
Tang, A. C., Reeb, B. C., Romeo, R. D., & McEwen, B. S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-23-08254.2003 · Cited by 80
“, 2000 ) , ACTH ( Gibbs , 1986 ) , and corticosterone release ( Windle et al .”
BackgroundInfluentialMarked differences in functioning of the hypothalamicpituitary-adrenal axis between groups of men
Petrides, J. S., Gold, P. W., Mueller, G. P., Singh, A., Stratakis, C., Chrousos, G. P., & Deuster, P. A. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.82.6.1979 · Cited by 77
SIRINATHSINGHJI, D. J. S. (1985) · Brain Research · doi:10.1016/0006-8993(85)90414-7 · Cited by 78
WYNN, P. C., HARWOOD, J. P., CATT, K. J., & AGUILERA, G. (1988) · Endocrinology · doi:10.1210/endo-122-1-351 · Cited by 78
Derick, S., Cheng, L. L., Voirol, M. J., Stoev, S., Giacomini, M., Wo, N. C., Szeto, H. H., Ben Mimoun, M., Andres, M., Gaillard, R. C., et al. (2002) · Endocrinology · doi:10.1210/en.2002-220363 · Cited by 76
“AVP is also known to potentiate CRF-induced ACTH secretion by corticotrophs (33).”
BackgroundField-Deployable Sniffer for 2,4-Dinitrotoluene Detection
Albert, K. J., Myrick, M. L., Brown, S. B., James, D. L., Milanovich, F. P., & Walt, D. R. (2001) · Environmental Science & Technology · doi:10.1021/es010829t · Cited by 76
Raadsheer, F. C., Oorschot, D. E., Verwer, R. W. H., Tilders, F. J. H., & Swaab, D. F. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903390311 · Cited by 76
SIRINATHSINGHJI, D. J. S. (1987) · Brain Research · doi:10.1016/0006-8993(87)91236-4 · Cited by 80
Vasopressin analgesia: Specificity of action and non-opioid effects
Kordower, J. H., & Bodnar, R. J. (1984) · Peptides · doi:10.1016/0196-9781(84)90017-2 · Cited by 84
Insulin hypersensitivity in mice lacking the V1b vasopressin receptor
Fujiwara, Y., Hiroyama, M., Sanbe, A., Aoyagi, T., Birumachi, J., Yamauchi, J., Tsujimoto, G., & Tanoue, A. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.136481 · Cited by 75
“…hormone [Arg8]-vasopressin (AVP) is known to promote vascular smooth muscle cell contraction, water reabsorption in the kidney and adrenocorticotropic hormone (ACTH) release from the anterior pituitary gland (Altura & Altura, 1977; Gillies et al. 1982; Schrier et al. 1993; Nielsen et al. 1995).”
BackgroundCoordinate Hormonal and Synaptic Regulation of Vasopressin Messenger RNA
Baldino, F., O'Kane, T. M., Fitzpatrick-McElligott, S., & Wolfson, B. (1988) · Science · doi:10.1126/science.3406747 · Cited by 75
Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community
Roussel, R., Boustany, R. E., Bouby, N., Potier, L., Fumeron, F., Mohammedi, K., Balkau, B., Tichet, J., Bankir, L., Marre, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1113 · Cited by 78
Murphy, D., Bishop, A. E., Rindi, G., Murphy, M. N., Stamp, G., Hanson, J. W., Polak, J. M., & Hogan, B. L. M. (1987) · PubMed Central · Cited by 74
Holsboer, F. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb08556.x · Cited by 73
Larsen, P. J., Jessop, D., Patel, H., Lightman, S. L., & Chowdrey, H. S. (1993) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1993.tb00368.x · Cited by 73
De Goeij, D. C., Binnekade, R., & Tilders, F. J. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.263.2.e394 · Cited by 74
Harbuz, M. S., Jessop, D. S., Lightman, S. L., & Chowdrey, H. S. (1994) · Brain Research · doi:10.1016/0006-8993(94)91707-8 · Cited by 78
McCann, S. M., Antunes-Rodrigues, J., Franci, C. R., Anselmo-Franci, J. A., Karanth, S., & Rettori, V. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000001000001 · Cited by 72
“Vasopressin can potentiate the response to CRH at the pituitary level as revealed by both in vivo (14) and in vitro experiments (15).”
BackgroundBuckingham, J. C. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15360.x · Cited by 72
Dimerization Between Vasopressin V1b and Corticotropin Releasing Hormone Type 1 Receptors
Young, S. F., Griffante, C., & Aguilera, G. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9135-8 · Cited by 71
“dents and human, AVP is a weak stimulant on its own but potentiates the stimulatory effect of CRH (Gillies et al., 1982).”
Yulis, C. R., & Lederis, K. P. (1987) · Cell and Tissue Research · doi:10.1007/bf00218308 · Cited by 71
KNEPEL, W., HOMOLKA, L., VLASKOVSKA, M., & NUTTO, D. (1984) · Endocrinology · doi:10.1210/endo-114-5-1797 · Cited by 71
Evaluation of the Hypothalamic-Pituitary-Adrenal Axis Function in Childhood and Adolescence
Chrousos, G. P., Kino, T., & Charmandari, E. (2009) · Neuroimmunomodulation · doi:10.1159/000216185 · Cited by 70
“(fig. 1 b). AVP, although a potent synergistic factor of CRH, has very little ACTH secretagogue activity on its own [”
BackgroundJarcho, M. R., Mendoza, S. P., Mason, W. A., Yang, X., & Bales, K. L. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00677.x · Cited by 70
“Increasing doses of exogenous AVP result in correspondingly increasing ACTH responses (Gillies et al. 1982; Turkelson et al. 1982).”
BackgroundPinnock, S. B., & Herbert, J. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01406.x · Cited by 70
“The importance of parvocellular AVP lies in its synergistic action, with CRF, on a number of dependent functions (Gillies et al., 1982).”
BackgroundFryer, J. N., Lederis, K. P., & Rivier, J. (1985) · Regulatory Peptides · doi:10.1016/0167-0115(85)90026-6 · Cited by 70
Yasin, S., Costa, A. C., BESSER, G. M., Hucks, D., Grossman, A. B., & Forsling, M. L. (1993) · Endocrinology · doi:10.1210/endo.132.3.8440190 · Cited by 70
RITTMASTER, R. S., CUTLER, G. B., GOLD, P. W., BRANDON, D. D., TOMAI, T., LORIAUX, D. L., & CHROUSOS, G. P. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-2-371 · Cited by 71
Aoki, Y., Iwasaki, Y., Katahira, M., Oiso, Y., & Saito, H. (1997) · Endocrinology · doi:10.1210/endo.138.5.5121 · Cited by 70
Ma, X., & Aguilera, G. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00080-7 · Cited by 69
CANNY, B. J., FUNDER, J. W., & CLARKE, I. J. (1989) · Endocrinology · doi:10.1210/endo-125-5-2532 · Cited by 69
Hypothalamic-pituitary-adrenal axis function during perinatal depression
Leff, P., Flores‐Ramos, M., López‐Martínez, M., Cruz-Fuentes, C. S., & Reyes‐Grajeda, J. P. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1508-2 · Cited by 70
“In addition, AVP released from the SON may induce ACTH release from the pituitary([59]).”
BackgroundCaraty, A., Grino, M., Locatelli, A., & Oliver, C. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80572-2 · Cited by 67
Hatzinger, M. (2000) · The World Journal of Biological Psychiatry · doi:10.3109/15622970009150573 · Cited by 52
Protein Kinase C Mediates the Effect of Vasopressin in Pituitary Corticotrophs
Carvallo, P., & Aguilera, G. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-12-1935 · Cited by 67
Pavlatou, M. G., Mastorakos, G., Lekakis, I., Liatis, S., Vamvakou, G., Zoumakis, E., Papassotiriou, I., Rabavilas, A. D., Katsilambros, N., & Chrousos, G. P. (2008) · Stress · doi:10.1080/10253890701476621 · Cited by 66
“Vasopressin secreted into the hypophysial portal circulation synergizes with CRH, enhancing the secretion of ACTH (Gillies et al. 1982; Liu et al. 1983).”
BackgroundNewson, M. J. F., Roberts, E., Pope, G. R., Lolait, S. J., & O’Carroll, A. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0093 · Cited by 66
Metadata
- Authors
- Gillies, G. E., Linton, E. A., & Lowry, P. J.
- Affiliations
- St Bartholomew's Hospital (GB)
- ORCID
- Linton, E. A.
- Venue
- Nature
- Published
- 1982-09
- Volume
- 299
- Issue
- 5881
- Pages
- 355-357
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2088159839
- Cited by
- 965
- References
- 20
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 6 · 2023: 10 · 2022: 12 · 2021: 7 · 2020: 12 · 2019: 16 · 2018: 10 · 2017: 16 · 2016: 20 · 2015: 12 · 2014: 20 · 2013: 16 · 2012: 17
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Keywords
- corticotropin-releasing factor, vasopressin, hypothalamic neuropeptides, hypothalamic extract, hypothalamic-pituitary-adrenal axis
- MeSH terms
- Adrenocorticotropic Hormone, Animals, Corticotropin-Releasing Hormone, Dose-Response Relationship, Drug, Drug Synergism, Hypothalamus, Vasopressins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.